The hottest stock in the S&P 500 this year has been Moderna (NASDAQ:MRNA), soaring well over 600% thus far. Investors have been bullish on the company's growth prospects again, this time due to a cancer vaccine it's been working on with Merck (NYSE:MRK), whose cancer drug Keytruda has generated tens of billions of dollars. Data from recent clinical trials has investors optimistic that the vaccine could bring in a boatload of revenue for Moderna, potentially giving the healthcare company the long-term growth catalyst it has desperately needed. While its COVID vaccine gave it a temporary boost, this could be a much more sustainable growth opportunity. While it looks probable that the vaccine will obtain approval given its encouraging results, there could still be a big obstacle to its long-term success: producing it in high quantities.
CryptoAlerta — análise de criptomoedas e mercado em tempo real